The FDA awarded a label expansion for Roche Holding AG's cobas EGFR mutation test to be used as a companion diagnostic with London-based Astrazeneca plc's non-small-cell lung cancer (NSCLC) treatment, Tagrisso (osimertinib), an approval that brings together two firms competing in the NSCLC treatment market, which is slated to grow to about $7.9 billion in 2020, according to a report from Global Business Intelligence.